Founder of CryptoMedix, Inc., Bernd Robert Seizinger currently is Chairman at Oxford BioTherapeutics Ltd.

He is also Executive Chairman & Chief Executive Officer at CryptoMedix, Inc. and on the board of 8 other companies.

In his past career he was Chief Scientific Officer & Executive VP at Oscient Pharmaceuticals Corp., President & Chief Executive Officer at GPC Biotech AG, Director-Molecular Neuro-Oncology Laboratory at The General Hospital Corp., VP-Oncology Drug Discovery & Academic Alliances at Bristol-Myers Squibb Pharmaceutical Research Institute, Principal at Princeton University and Associate Director at Harvard Medical School.

Dr. Seizinger received a doctorate from Max-Planck-Institute for Molecular Genetics and a doctorate from Ludwig-Maximilians-Universität München.